» Articles » PMID: 37328533

HIV Status and Survival of Patients with Pulmonary Hypertension Due to Left Heart Disease: the Pan African Pulmonary Hypertension Cohort

Overview
Journal Sci Rep
Specialty Science
Date 2023 Jun 16
PMID 37328533
Authors
Affiliations
Soon will be listed here.
Abstract

In sub-Saharan Africa, little is known about pulmonary hypertension in left heart disease (PH-LHD). We used multivariate logistic and cox-hazard proportional regression models to examine factors associated with increased right ventricular systolic pressure (RVSP) and the effect of real-world HIV status scenarios on 6-month survival rate in the Pan African Pulmonary Hypertension Cohort (PAPUCO) study, a prospective cohort from four African countries. Exposure to biomass fuel smoke (aOR, 95%CI 3.07, 1.02-9.28), moderate to severe NYHA/FC III/IV (aOR, 95%CI 4.18, 1.01-17.38), and unknown HIV status (aOR, 95%CI 2.73, 0.96-7.73) predicted moderate to severe RVSP at the time of presentation. Six months later, HIV infection, moderate-to-severe NYHA/FC, and alcohol consumption were associated with decreased survival probabilities. Upon adjusting for HIV infection, it was observed that an incremental rise in RVSP (1 mmHg) and inter-ventricular septal thickness (1 mm) resulted in an 8% (aHR, 95%CI 1.08, 1.02-1.13) and 20% (aHR, 95%CI 1.2, 1.00-1.43) increase in the probability of mortality due to PH-LHD. In contrast, the risk of death from PH-LHD was reduced by 23% for each additional unit of BMI. (aHR, 95%CI 0.77, 0.59-1.00). In conclusion, the present study offers insights into the determinants that are notably linked to unfavorable survival outcomes in patients with pulmonary hypertension due to left heart disease. Certain factors identified in this study are readily evaluable and amenable to modification, even in settings with limited resources.

Citing Articles

Pulmonary Hypertension: Pharmacological and Non-Pharmacological Therapies.

Tsai J, Malik S, Tjen-A-Looi S Life (Basel). 2024; 14(10).

PMID: 39459565 PMC: 11509317. DOI: 10.3390/life14101265.

References
1.
Watkins D, Johnson C, Colquhoun S, Karthikeyan G, Beaton A, Bukhman G . Global, Regional, and National Burden of Rheumatic Heart Disease, 1990-2015. N Engl J Med. 2017; 377(8):713-722. DOI: 10.1056/NEJMoa1603693. View

2.
Gordon S, Bruce N, Grigg J, Hibberd P, Kurmi O, Hubert Lam K . Respiratory risks from household air pollution in low and middle income countries. Lancet Respir Med. 2014; 2(10):823-60. PMC: 5068561. DOI: 10.1016/S2213-2600(14)70168-7. View

3.
Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):.... Eur Heart J. 2015; 37(1):67-119. DOI: 10.1093/eurheartj/ehv317. View

4.
Thienemann F, Dzudie A, Mocumbi A, Blauwet L, Sani M, Karaye K . Rationale and design of the Pan African Pulmonary hypertension Cohort (PAPUCO) study: implementing a contemporary registry on pulmonary hypertension in Africa. BMJ Open. 2015; 4(10):e005950. PMC: 4202005. DOI: 10.1136/bmjopen-2014-005950. View

5.
Szwejkowski B, Elder D, Shearer F, Jack D, Choy A, Pringle S . Pulmonary hypertension predicts all-cause mortality in patients with heart failure: a retrospective cohort study. Eur J Heart Fail. 2011; 14(2):162-7. DOI: 10.1093/eurjhf/hfr159. View